Specify a stock or a cryptocurrency in the search bar to get a summary
Herantis Pharma Oyj
HRTISHerantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland. Address: Bertel Jungin Aukio 1, Espoo, Finland, 02600
Analytics
WallStreet Target Price
1.41 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures HRTIS
Dividend Analytics HRTIS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History HRTIS
Stock Valuation HRTIS
Financials HRTIS
Results | 2019 | Dynamics |